The high court noted that SMA is a debilitating disease which has no cure, and the only approved drug, Risdiplam, marketed ...

For this single case, the FDA approved the early administration of the oral drug risdiplam, brand name Evrysdi, owned by the ...

The FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision due by 24 May next year. If approved, risdiplam will be the third drug to be ...

The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.

Roche had appealed against a single judge order of March 24 that had refused to stop Natco Pharma from manufacturing a generic version of Risdiplam ...

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...

While Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market for spinal muscular atrophy (SMA) treatments, Novartis’ research chief Jay Bradner has a ...

The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy ...

Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...

About Evrysdi ® (risdiplam) Evrysdi is a survival motor neuron 2 (SMN2) pre-mRNA splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to survival of motor neuron ...

Delhi HC rejects interim injunction plea from Roche against Natco's SMA drug Evrysdi: Our Bureau, New Delhi Thursday, March 27, 2025, 08:00 Hrs [IST] The Delhi High Court has reje ...

In a major relief to Indian drugmaker Natco Pharma, the Delhi High Court has rejected an interim injunction plea filed by ...